ESR1 and breast cancer: Among ERα+ tumor types, loss of PGR expression correlates with aberrant estrogen signaling, and we show that AGO2 expression in an ERα+ breast cancer cell line can repress classical ERα signaling (loss of ERα expression and loss of E2 stimulation of PGR; Figure 2).